beacon pharmaceuticals limited
beacon pharmaceuticals limited Company Information
Company Number
03953215
Registered Address
the bower 4 roundwood avenue, stockley park, heathrow, UB11 1AF
Industry
Manufacture of pharmaceutical preparations
Telephone
08454375565
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
kent pharmaceutical ltd 100%
beacon pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of BEACON PHARMACEUTICALS LIMITED at £0 based on a Turnover of £0 and 1.15x industry multiple (adjusted for size and gross margin).
beacon pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of BEACON PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £0 and a 5.27x industry multiple (adjusted for size and gross margin).
beacon pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of BEACON PHARMACEUTICALS LIMITED at £2.7m based on Net Assets of £1.2m and 2.17x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Beacon Pharmaceuticals Limited Overview
Beacon Pharmaceuticals Limited is a live company located in heathrow, UB11 1AF with a Companies House number of 03953215. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in March 2000, it's largest shareholder is kent pharmaceutical ltd with a 100% stake. Beacon Pharmaceuticals Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Beacon Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Beacon Pharmaceuticals Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 1 areas for improvement. Company Health Check FAQs
1 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Beacon Pharmaceuticals Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Beacon Pharmaceuticals Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Beacon Pharmaceuticals Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Beacon Pharmaceuticals Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (157)
- Beacon Pharmaceuticals Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Beacon Pharmaceuticals Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Beacon Pharmaceuticals Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Beacon Pharmaceuticals Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Beacon Pharmaceuticals Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Beacon Pharmaceuticals Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Beacon Pharmaceuticals Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0.1%, this is a lower level of debt than the average (45.7%)
- - Beacon Pharmaceuticals Limited
- - Industry AVG
BEACON PHARMACEUTICALS LIMITED financials
Beacon Pharmaceuticals Limited's latest turnover from March 2023 is 0 and the company has net assets of £1.2 million. According to their latest financial statements, we estimate that Beacon Pharmaceuticals Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 0 | ||||||||||
| Other Income Or Grants | 0 | 0 | 0 | |||||||||||
| Cost Of Sales | 0 | 0 | 0 | |||||||||||
| Gross Profit | 0 | 0 | 0 | |||||||||||
| Admin Expenses | 0 | 0 | 0 | |||||||||||
| Operating Profit | 0 | -1,000 | 0 | 0 | ||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | ||||||||||
| Interest Receivable | 0 | 0 | 0 | 0 | ||||||||||
| Pre-Tax Profit | 0 | -1,000 | 0 | 0 | ||||||||||
| Tax | 0 | 0 | 0 | 0 | ||||||||||
| Profit After Tax | 0 | -1,000 | 0 | 0 | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | ||||||||||
| Retained Profit | 0 | -1,000 | 0 | 0 | ||||||||||
| Employee Costs | 0 | 0 | 0 | |||||||||||
| Number Of Employees | ||||||||||||||
| EBITDA* | 0 | -1,000 | 0 | 0 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,882 | 993 | 3,796 | 3,779 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 320,833 | 670,833 | 1,020,833 | 670,833 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 323,715 | 671,826 | 1,024,629 | 674,612 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 882,182 | 1,085,683 | 1,003,909 | 1,390,624 | 995,320 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 445,317 | 545,277 | 505,961 | 752,035 | 801,416 |
| Group Debtors | 1,239,000 | 1,239,000 | 1,239,000 | 1,239,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 884,529 | 1,702,699 | 2,699,912 | 833,738 | 1,425,910 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 1,239,000 | 1,239,000 | 1,239,000 | 1,239,000 | 0 | 0 | 0 | 0 | 0 | 2,212,028 | 3,333,659 | 4,209,782 | 2,976,397 | 3,222,646 |
| total assets | 1,239,000 | 1,239,000 | 1,239,000 | 1,239,000 | 0 | 0 | 0 | 0 | 0 | 2,212,028 | 3,657,374 | 4,881,608 | 4,001,026 | 3,897,258 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,638,428 | 902,362 | 2,156,939 | 1,600,683 | 1,245,945 |
| Group/Directors Accounts | 1,000 | 1,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 175 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 1,000 | 1,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,638,428 | 902,362 | 2,156,939 | 1,600,683 | 1,246,120 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 51 | 663 | 44 | 0 | 507 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 51 | 663 | 44 | 0 | 507 |
| total liabilities | 1,000 | 1,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,638,479 | 903,025 | 2,156,983 | 1,600,683 | 1,246,627 |
| net assets | 1,238,000 | 1,238,000 | 1,239,000 | 1,239,000 | 0 | 0 | 0 | 0 | 0 | 573,549 | 2,754,349 | 2,724,625 | 2,400,343 | 2,650,631 |
| total shareholders funds | 1,238,000 | 1,238,000 | 1,239,000 | 1,239,000 | 0 | 0 | 0 | 0 | 0 | 573,549 | 2,754,349 | 2,724,625 | 2,400,343 | 2,650,631 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Apr 2014 | Apr 2013 | Apr 2012 | Apr 2011 | Apr 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 0 | -1,000 | 0 | 0 | ||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 2,882 | 3,866 | 2,803 | 4,424 | 1,798 | |||||
| Amortisation | 0 | 0 | 0 | 0 | 320,833 | 350,000 | 350,000 | 350,000 | 29,167 | |||||
| Tax | 0 | 0 | 0 | 0 | ||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -882,182 | -203,501 | 81,774 | -386,715 | 395,304 | 995,320 |
| Debtors | 0 | 0 | 0 | 1,239,000 | 0 | 0 | 0 | 0 | -445,317 | -99,960 | 39,316 | -246,074 | -49,381 | 801,416 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,638,428 | 736,066 | -1,254,577 | 556,256 | 354,738 | 1,245,945 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -51 | -612 | 619 | 44 | -507 | 507 |
| Cash flow from operations | 0 | -1,000 | 0 | -1,239,000 | ||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 1,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -175 | 175 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 0 | 0 | 0 | 0 | ||||||||||
| cash flow from financing | 0 | 1,000 | 0 | 1,239,000 | ||||||||||
| cash and cash equivalents | ||||||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -884,529 | -818,170 | -997,213 | 1,866,174 | -592,172 | 1,425,910 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -884,529 | -818,170 | -997,213 | 1,866,174 | -592,172 | 1,425,910 |
beacon pharmaceuticals limited Credit Report and Business Information
Beacon Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for beacon pharmaceuticals limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
beacon pharmaceuticals limited Ownership
BEACON PHARMACEUTICALS LIMITED group structure
Beacon Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
2 parents
BEACON PHARMACEUTICALS LIMITED
03953215
beacon pharmaceuticals limited directors
Beacon Pharmaceuticals Limited currently has 4 directors. The longest serving directors include Mr David Wright (Sep 2019) and Mr David Wright (Sep 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr David Wright | England | 60 years | Sep 2019 | - | Director |
| Mr David Wright | England | 60 years | Sep 2019 | - | Director |
| Mr David Wright | England | 60 years | Sep 2019 | - | Director |
| Mr Kevin James | United Kingdom | 69 years | Mar 2022 | - | Director |
P&L
March 2023turnover
0
0%
operating profit
0
-100%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
1.2m
0%
total assets
1.2m
0%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
beacon pharmaceuticals limited company details
company number
03953215
Type
Private limited with Share Capital
industry
21200 - Manufacture of pharmaceutical preparations
incorporation date
March 2000
age
24
accounts
Audit Exemption Subsidiary
ultimate parent company
previous names
N/A
incorporated
UK
address
the bower 4 roundwood avenue, stockley park, heathrow, UB11 1AF
last accounts submitted
March 2023
beacon pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to beacon pharmaceuticals limited. Currently there are 2 open charges and 0 have been satisfied in the past.
beacon pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
